FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013482392> ?p ?o ?g. }

• W3013482392 abstract "Aim: The aim of this study was to compare the long-term outcome of women with primary or locally advanced breast cancer randomised to receive either doxorubicin and cyclophosphamide (AC) or doxorubicin and docetaxel (AD) as primary chemotherapy. Patients and methods: Eligible patients with histology-proven breast cancer with primary tumours ≥ 3 cm, inflammatory or locally advanced disease, and no evidence of distant metastases, were randomised to receive a maximum of 6 cycles of either doxorubicin (60 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) i/v or doxorubicin (50 mg/m(2)) plus docetaxel (75 mg/m(2)) i/v every 3 weeks, followed by surgery on completion of chemotherapy. Results: Clinical and pathologic responses have previously been reported 1. Time to relapse, site of relapse, and all-cause mortality were recorded. This updated analysis compares long-term disease-free (DFS) and overall survival (OS) using stratified log rank methods. A total of 363 patients were randomised to AC (n = 181) or AD (n = 182). At a median follow-up of 119 months, there is no significant difference between the two groups for DFS (P = 0.274) and OS (P = 0.327). The 10-year DFS for AC is 54% (95% CI 47-62%) and for AD 60% (95% CI 52-67). The 10-year OS is 49% (95% CI 42-57%) for AC and 51% (95% CI 43-58%) for AD. Metastatic breast cancer accounted for 89% of deaths in those treated with AC and 86% in those treated with AD. Estrogen receptor (ER) and nodal status were independent prognostic factors for DFS and OS (p Conclusions: This was one of the first studies to evaluate taxanes versus anthracyclines in the neoadjuvant setting. Our mature data do not support an added clinical benefit for the simultaneous administration of AD compared to AC. This supports current practice with respect to sequential treatment with taxanes followed by anthracyclines leading to an increase in pathological complete response rate and better survival outcomes. 1. Evans TR, Yellowlees A, Foster E et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic cooperative Oncology group study. J Clin Oncol 2005, 23: 2988–2995. Citation Format: Chara Stavraka, T. R. Jeffry Evans, Joanna Dunlop, Helena Earl, David A. Cameron, Robert E Coleman, Timothy Perren, Robert CF Leonard, Janine L Mansi. 10-year outcome for women randomized in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An anglo-celtic cooperative oncology group study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-16-15." @default.
• W3013482392 created "2020-04-03" @default.
• W3013482392 creator A5007286394 @default.
• W3013482392 creator A5010813520 @default.
• W3013482392 creator A5014220064 @default.
• W3013482392 creator A5015824949 @default.
• W3013482392 creator A5023179046 @default.
• W3013482392 creator A5030290080 @default.
• W3013482392 creator A5051980635 @default.
• W3013482392 creator A5082292420 @default.
• W3013482392 creator A5083306545 @default.
• W3013482392 date "2020-02-14" @default.
• W3013482392 modified "2023-10-02" @default.
• W3013482392 title "Abstract P2-16-15: 10-year outcome for women randomized in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An anglo-celtic cooperative oncology group study" @default.
• W3013482392 doi "https://doi.org/10.1158/1538-7445.sabcs19-p2-16-15" @default.
• W3013482392 hasPublicationYear "2020" @default.
• W3013482392 type Work @default.
• W3013482392 sameAs 3013482392 @default.
• W3013482392 citedByCount "0" @default.
• W3013482392 crossrefType "proceedings-article" @default.
• W3013482392 hasAuthorship W3013482392A5007286394 @default.
• W3013482392 hasAuthorship W3013482392A5010813520 @default.
• W3013482392 hasAuthorship W3013482392A5014220064 @default.
• W3013482392 hasAuthorship W3013482392A5015824949 @default.
• W3013482392 hasAuthorship W3013482392A5023179046 @default.
• W3013482392 hasAuthorship W3013482392A5030290080 @default.
• W3013482392 hasAuthorship W3013482392A5051980635 @default.
• W3013482392 hasAuthorship W3013482392A5082292420 @default.
• W3013482392 hasAuthorship W3013482392A5083306545 @default.
• W3013482392 hasConcept C121608353 @default.
• W3013482392 hasConcept C126322002 @default.
• W3013482392 hasConcept C141071460 @default.
• W3013482392 hasConcept C143998085 @default.
• W3013482392 hasConcept C2776694085 @default.
• W3013482392 hasConcept C2776755627 @default.
• W3013482392 hasConcept C2781190966 @default.
• W3013482392 hasConcept C2781303535 @default.
• W3013482392 hasConcept C530470458 @default.
• W3013482392 hasConcept C71924100 @default.
• W3013482392 hasConceptScore W3013482392C121608353 @default.
• W3013482392 hasConceptScore W3013482392C126322002 @default.
• W3013482392 hasConceptScore W3013482392C141071460 @default.
• W3013482392 hasConceptScore W3013482392C143998085 @default.
• W3013482392 hasConceptScore W3013482392C2776694085 @default.
• W3013482392 hasConceptScore W3013482392C2776755627 @default.
• W3013482392 hasConceptScore W3013482392C2781190966 @default.
• W3013482392 hasConceptScore W3013482392C2781303535 @default.
• W3013482392 hasConceptScore W3013482392C530470458 @default.
• W3013482392 hasConceptScore W3013482392C71924100 @default.
• W3013482392 hasLocation W30134823921 @default.
• W3013482392 hasOpenAccess W3013482392 @default.
• W3013482392 hasPrimaryLocation W30134823921 @default.
• W3013482392 hasRelatedWork W12266645 @default.
• W3013482392 hasRelatedWork W13998030 @default.
• W3013482392 hasRelatedWork W14228319 @default.
• W3013482392 hasRelatedWork W15521606 @default.
• W3013482392 hasRelatedWork W3598312 @default.
• W3013482392 hasRelatedWork W8234051 @default.
• W3013482392 hasRelatedWork W8791024 @default.
• W3013482392 hasRelatedWork W9309986 @default.
• W3013482392 hasRelatedWork W9962084 @default.
• W3013482392 hasRelatedWork W19634549 @default.
• W3013482392 isParatext "false" @default.
• W3013482392 isRetracted "false" @default.
• W3013482392 magId "3013482392" @default.
• W3013482392 workType "article" @default.